Hope in Alzheimer's Research

This chapter explores the rise in life expectancy and the associated increase in age-related diseases like dementia, focusing on the promising drug licanumab for Alzheimer's treatment. It discusses the drug's trial results that suggest it may significantly slow symptom progression while addressing the complexities and uncertainties of transitioning from clinical trials to real-world application. The chapter also reflects on the implications of the amyloid hypothesis and touches upon the broader economic issues impacting healthcare availability and affordability.